Rznomics Company Description

Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases.

Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome.

Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si, South Korea.